Wockhardt Ltd (WOCKPHARMA) — shareholding pattern, promoter holding, financials and share price
About Wockhardt Ltd (WOCKPHARMA)
Wockhardt Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as WOCKPHARMA and on the BSE under scrip code 532300. Its ISIN is INE049B01025.
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development.
The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly.
Listed peers in Pharmaceuticals: Emcure Pharmaceuticals Ltd, Acutaas Chemicals Ltd, Sai Life Sciences Ltd, Neuland Laboratories Ltd, Rubicon Research Ltd, Piramal Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,811.45 a share on 10 Jul 2026, Wockhardt Ltd (WOCKPHARMA) was valued at a price-to-earnings ratio of 147.91x against an industry P/E of 36.41x and a price-to-book of 6.76x on a book value of ₹267.89 per share as of Mar 2025. Solomo computes return on equity of 4.57% and return on capital employed of 7.08% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 147.91x
- Industry P/E
- 36.41x
- P/B
- 6.76x
- EPS (TTM)
- ₹12.25
- Book value / share
- ₹267.89
- ROE
- 4.57%
- ROCE
- 7.08%
- ROA
- 2.45%
- Debt / equity
- 0.46x
- Dividend yield
- 0%
- EBITDA margin
- 20.1%
- 52-week range
- ₹1,086.8 – ₹2,420
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Wockhardt Ltd (WOCKPHARMA) reported revenue of ₹3,373 crore, net profit of ₹199 crore and earnings per share of ₹13.11. That compares with revenue of ₹3,012 crore and net profit of ₹-57 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹965 crore and net profit ₹164 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 |
| Net profit (₹ cr) | -279 | -621 | -472 | -57 | 199 |
| EPS (₹) | -16.94 | -38.8 | -30.18 | -2.89 | 13.11 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -4.25% | 1.15% | -2.30% | 7.65% |
| Profit growth | - | - | - | 87.92% |
| Stock price CAGR | 8% | 29% | 99% | 3% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.08% of Wockhardt Ltd (WOCKPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 7.22% and domestic institutional investors (DII) hold 9.24%. Promoters have pledged 14.7% of their holding. Market capitalisation was ₹29,435 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Tata Mutual Fund - Tata Small Cap Fund 2.03%, Rekha Jhunjhunwala 1.75%, Hsbc Mutual Fund - Hsbc Small Cap Fund 1.3%, 3p India Equity Fund 1 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.08% | 14.7% | 7.22% | 9.24% | 50.92% |
| Mar 2026 | 49.08% | 18.8% | 7.09% | 10.96% | 50.92% |
| Dec 2025 | 49.08% | 18% | 6.99% | 10.55% | 50.92% |
| Sep 2025 | 49.08% | 21.3% | 7.1% | 11.01% | 50.92% |
| Jun 2025 | 49.09% | 15.6% | 7.29% | 11.01% | 50.91% |
| Mar 2025 | 49.09% | 18.2% | 6.81% | 10.59% | 50.91% |
| Dec 2024 | 49.09% | 17% | 6.54% | 9.82% | 50.91% |
| Sep 2024 | 51.99% | 33.6% | 6.7% | 5.09% | 48.01% |